Anika Therapeutics: U.S. Approval To Drive Profit And Valuation
KEMS Research - Seeking Alpha - Tue Dec 23, 5:45AM CST
Description Anika Therapeutics (NASDAQ: ANIK ) is a small cap, biotech company focused on commercializing hyaluronic acid (HA) based therapeutic solutions. HA is naturally present in human bodies and is found primarily in the skin,...
ANIK: 38.26 (+0.73), SNY: 46.35 (+0.50)
Alnylam Pharmaceuticals Continues To Post Encouraging Results
Stephen Simpson, CFA - at Seeking Alpha - Mon Dec 22, 11:15AM CST
ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21), ALXN: 181.96 (+3.09), SNY: 46.35 (+0.50)
Overvalued Bonds Or Would You Buy Stocks With A PE Of 100?
Seeking Early Retirement - at Seeking Alpha - Mon Dec 22, 8:31AM CST
BTI: 110.32 (+1.08), IEF: 105.25 (-0.08), COP: 70.13 (-0.92), MO: 50.36 (-0.17), GSK: 42.85 (+0.11), VOD: 34.65 (-0.05), PM: 83.15 (-0.15), T: 33.96 (-0.07), SPY: 207.77 (+0.02), RDS.A: 68.42 (-0.31), DIA: 180.03 (unch), BP: 38.95 (-0.17), SNY: 46.35 (+0.50), CVX: 113.47 (-0.48), VZ: 47.67 (unch)
Lieff Cabraser Announces Class Action Litigation Against Sanofi - SNY
Business Wire - Mon Dec 22, 8:00AM CST
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of those who purchased or otherwise acquired the securities of Sanofi ("Sanofi" or the "Company"
SNY: 46.35 (+0.50)
Buying These 3 Stocks Is Like Making a Bet in a Burning House
George Budwell, The Motley Fool - Motley Fool - Mon Dec 22, 7:54AM CST
Source: Flickr user Mark Esau Bargain hunters are often attracted to beaten-down biotech stocks because they sometimes rebound in astonishing fashion. That said, it can be extremely difficult to separate the wheat from the chaff when mulling over...
OREX: 5.98 (+0.01), AZN: 70.44 (+0.26), VVUS: 2.99 (-0.02), AMGN: 160.67 (+3.15), AEGR: 21.59 (-0.27), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18)
EQUITY ALERT: Rosen Law Firm Reminds Sanofi Investors of Important Class Action Deadline - SNY
GlobeNewswire - Sun Dec 21, 7:25PM CST
The Rosen Law Firm, a global investor-rights firm, reminds purchasers of Sanofi securities (NYSE:SNY) during the period from February 7, 2013 through December 3, 2014, of the important February 2, 2015 lead plaintiff deadline in the class action.
SNY: 46.35 (+0.50)
Why Is George Soros Buying This Beaten Down Biotech Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Dec 21, 10:04AM CST
Source: Wikimedia Commons/ Niccolò Caranti The controversial billionaire and hedge fund guru George Soros is undoubtedly one of the best investors on the planet today. At age 83, he is estimated to be the seventh-richest American, with a net...
PFE: 31.42 (-0.03), AZN: 70.44 (+0.26), SRPT: 13.88 (+0.47), AMGN: 160.67 (+3.15), AEGR: 21.59 (-0.27), SNY: 46.35 (+0.50)
SANOFI SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Sanofi -- SNY
GlobeNewswire - Sat Dec 20, 9:00PM CST
Kahn Swick & Foti, LLC ("KSF"
SNY: 46.35 (+0.50)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Sanofi of Class Action Lawsuit and Upcoming Deadline -- SNY
GlobeNewswire - Fri Dec 19, 4:12PM CST
Pomerantz LLP has filed a class action lawsuit against Sanofi ("Sanofi" or the "Company"
SNY: 46.35 (+0.50)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 340.89 (+5.13), VRX: 140.33 (-0.22), QLTI: 3.72 (+0.08), CTRX: 51.83 (+0.14), BCRX: 11.83 (+0.76), ACT: 254.20 (-1.68), MDT: 74.08 (+0.31), TKMR: 13.97 (+0.14), NEPT: 1.88 (+0.03), BSX: 13.13 (+0.07), AGN: 210.12 (+0.95), CMRX: 36.80 (+0.70), ALNY: 93.52 (+0.97), SRPT: 13.88 (+0.47), SHPG: 209.29 (+0.07), NLNK: 39.08 (+1.36), SNY: 46.35 (+0.50), MSLI: 1.67 (+0.02), NVCN: 6.60 (unch), CRME: 8.56 (+0.06), EBS: 27.64 (+1.28), GSK: 42.85 (+0.11), CELG: 109.60 (+3.48), GILD: 91.29 (+1.84), MRK: 57.46 (+0.25), NVDQ: 16.90 (+0.55), NVS: 93.91 (+0.66)
The Best Healthcare Stocks of 2014: Which Is Our Favorite for 2015?
Todd Campbell, The Motley Fool - Motley Fool - Fri Dec 19, 6:44AM CST
From Medicaid expansion to cancer drugs to minimally invasive treatment for heart disease, Industry Focus looks at the 10 top performers among large-cap healthcare stocks in 2014. There were some surprises on the list this year, with strong showings...
AGN: 210.12 (+0.95), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), JNJ: 104.59 (+0.31), VRX: 140.33 (-0.22), ACT: 254.20 (-1.68), EW: 130.75 (+1.17), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07)
5 Big Stocks to Trade After the Fed's Rate News: Microsoft, Goldman and More
at The Street - Thu Dec 18, 11:08AM CST
Here's a closer technical look at five big stocks to trade for gains.
BRO: 32.76 (-0.02), GS: 195.89 (+0.39), UBS: 17.61 (+0.11), SNY: 46.35 (+0.50), MSFT: 48.14 (-0.31)
Cramer's Lightning Round - Why Did They Fire The Nice Man At Sanofi? (12/17/14)
SA Editor Miriam Metzinger - Seeking Alpha - Thu Dec 18, 5:08AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday December 17. Bullish Calls: General Electric (NYSE: GE ): "It is a good stock with a good yield." Bristol Myers (NYSE: BMY ): ...
NLY: 11.21 (-0.05), BCRX: 11.83 (+0.76), GE: 25.83 (-0.05), DDD: 30.54 (-0.64), BMY: 59.15 (-0.01), SNY: 46.35 (+0.50)
'Mad Money' Lightning Round: GE Is a Good Stock With Good Yield
at The Street - Thu Dec 18, 5:00AM CST
Cramer is skittish on Sanofi, can't recommend C&J Energy Services and doesn't want you in Annaly Capital.
NLY: 11.21 (-0.05), GE: 25.83 (-0.05), CJES: 13.39 (-0.29), BCRX: 11.83 (+0.76), DDD: 30.54 (-0.64), AGIO: 109.67 (+2.45), ABBV: 66.21 (+1.86), BMY: 59.15 (-0.01), SNY: 46.35 (+0.50), HPQ: 40.54 (+0.18), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)
Jim Cramer's 'Mad Money' Recap: Why This Market Is All About Velocity
at The Street - Wed Dec 17, 7:16PM CST
A day's rest from the selling in oil will allow investors, analysts and oil companies themselves some time to assess their situations, Cramer says.
MNST: 112.56 (+0.52), BCRX: 11.83 (+0.76), CJES: 13.39 (-0.29), GE: 25.83 (-0.05), CLX: 105.46 (-0.62), DDD: 30.54 (-0.64), KMB: 117.77 (-0.21), RRD: 16.84 (+0.07), BMY: 59.15 (-0.01), KS: 29.97 (+0.03), HPQ: 40.54 (+0.18), CELG: 109.60 (+3.48), HAIN: 117.25 (+0.23), NLY: 11.21 (-0.05), CVS: 97.89 (+0.02), ABBV: 66.21 (+1.86), AGIO: 109.67 (+2.45), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07)
2 Reasons On Why European Stocks Have Room To Grow
David Hunkar - Seeking Alpha - Wed Dec 17, 10:51AM CST
European stocks have been laggards this years relative to the decent performance of U.S. stocks. However moving forward, European stocks have better growth potential compared to their American peers for a variety of reasons two of which are discussed...
E: 36.10 (-0.25), SAN: 8.72 (+0.05), TEF: 14.81 (-0.02), SNY: 46.35 (+0.50)
3 Companies Growing Faster Than MannKind Corporation
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 17, 6:03AM CST
Source: MannKind. MannKind shareholders have had quite the year. After more than doubling in the first half of the year, shares have since given back all of their gains and sit essentially unchanged. Despite the stalemate, MannKind could be on...
AKRX: 36.47 (+0.43), ALXN: 181.96 (+3.09), ACOR: 39.14 (+0.74), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Sanofi To Contact Brower Piven Before The February 2, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Dec 16, 3:31PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Sanofi ("Sanofi" or the "Company"
SNY: 46.35 (+0.50)
Alnylam Provides Pipeline Update, Growth Strategy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 4:50PM CST
Alnylam (ALNY) announced a strategy for developing its RNAi therapeutics in three strategic therapeutic areas (STArs): genetic medicines, cardio-metabolic disease and hepatic infectious disease.
ALNY: 93.52 (+0.97), MDCO: 27.06 (+0.21), AMGN: 160.67 (+3.15), SNY: 46.35 (+0.50)
3 Healthcare Stocks to Watch in 2015
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 15, 8:41AM CST
Source: Sanofi. The end of the year brings with it yuletide cheer, gatherings with friends and families, and perhaps even the swapping of holiday gifts. For healthcare investors, the end of the year also brings with it time to reflect on the year...
GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18), EXEL: 1.29 (-0.01)